Drug-maker Cipla has expanded its collaboration with Swedish drug company Meda in the segment of allergic rhinitis, or allergies affecting the nasal airways. The two companies will build further on the existing collaboration by granting global commercialisation rights to Meda for Dymista nasal spray, excluding some markets for which Cipla will take the commercial lead, a note from Cipla said. They would also collaborate on follow-up compounds for Dymista, capitalising on the intellectual property retained by both partners, the note added.

Related Topics